News
The Minister of Development and Technology has decided to maintain Biostat's status as a research and development (R&D) center. Currently, only 61 Polish companies hold this prestigious title.
In Poland, companies that are not research institutes but conduct research or development activities can obtain R&D center status.
Companies with R&D center status provide technical and scientific support to various sectors, such as pharmaceuticals, medicine, energy, mining machinery production, IT, engineering, and fintech. Their common trait is their commitment to research and development activities.
Companies that already hold R&D center status must reapply each year to retain the title. They undergo a thorough evaluation by the Minister of Development and Technology, which assesses the company's financial health and ongoing research and development activities.
Biostat has retained its R&D center status for the 6th consecutive year. This is the result of our collaboration with leading Polish academic institutions and research institutes, supporting research projects in areas such as statistics, artificial intelligence algorithms, and machine learning.
In 2023, we carried out numerous significant R&D works and services in the fields of clinical research support, new IT solutions, Big Data, Statistics, and process automation in innovation and research and development. We executed many projects with universities, research centers, innovative service providers, and the business world. Our solutions continue to provide technical and scientific support in pharmaceuticals and medicine, especially in clinical trials and e-health, as well as in social sciences. Some of our innovative projects were directed toward international markets
- explains Rafał Piszczek, CEO of Biostat.
In 2023, we continued working with leading pharmaceutical companies, including Adamed, AstraZeneca, Celon Pharma, Chiesi, Egis, Ipsen, Pfizer, Polpharma, and Takeda.
Last year, we also established new partnerships. We signed a framework agreement with the Jagiellonian Innovation Center and an agreement with American Heart of Poland for long-term research collaboration. New Biostat clients also included organizations such as Medinice, Bioxapp, the Górnośląskie Medical Center of Prof. Leszek Giec at the Medical University of Silesia in Katowice, and Neuro Device Group S.A.
We continue to actively support non-commercial clinical trials for clients like the Medical University of Warsaw, Wrocław Medical University, Gdańsk Medical University, the National Institute of Oncology, the Jagiellonian University, University Clinical Hospital in Opole, Nicolaus Copernicus University in Toruń, the Silesian Center for Heart Diseases, and the Institute of Hematology and Transfusion Medicine.
Our strong position in clinical and observational research is also confirmed by publications supported by Biostat's statistical services in prestigious journals such as Therapeutic Advances in Gastroenterology (TAG), American Journal of Perinatology, Frontiers in Pediatrics, PLOS ONE, Neonatology, and Advances in Clinical and Experimental Medicine
- comments Edyta Klemba, Pharma Division Director at Biostat.
In 2023, the results of our research were included in reports from key consulting firms such as Grant Thornton and PwC, as well as in analyses from public think tanks, including the Polish Economic Institute, the Generation Institute, and the National Institute of Public Health – National Institute of Hygiene. Among our clients were institutions like the Voivodeship Labor Office in Białystok and the Open Cages Association.
Last year, we conducted around 100 scientific and social studies for leading Polish universities, including the University of Warsaw, Jagiellonian University, Gdańsk University of Technology, Lublin University of Technology, AGH University of Science and Technology, Warsaw School of Economics, Wrocław University of Economics, and WSB Merito University. Our work supports scientists in conducting both quantitative and qualitative research, as well as in the statistical analysis of results.
It’s worth noting that as an R&D center, Biostat has a full spectrum of research tools such as CATI, CAWI, CAPI, and PAPI. An additional advantage is our proprietary survey panel, Badanie-opinii.pl, which allows us to flexibly conduct even the most demanding projects
- emphasizes Monika Jaremków PhD, R&D Director at Biostat.
The 2023 software projects also contributed to Biostat’s continued status as an R&D center.
For several years, our strategic goal has been to build an international telemedicine platform and software that utilizes simulation and predictive models (big data/machine learning) to optimize patient diagnostics
- says Szymon Błąkała, R&D Director at Biostat.
As a result of this strategy and the work of Biostat programmers, more than 120 updates were made to the Medfile and HaloDoctor applications, which are used for managing medical facilities and providing telemedicine services. Many of the new features are directly based on AI algorithms, such as Drug Assistant, an AI solution that aids doctors in diagnosis and treatment selection.
AI technology is also the foundation of the Digital Twin of the Eye project, developed in collaboration with the Norwegian company ViciData. This project is based on the digital twin technology, which creates a digital model of physical products, systems, or processes. The concept could become a groundbreaking solution in diagnosing and treating eye diseases in the future. The Digital Twin of the Eye project has been recognized by The Industrial Development Corporation of Norway (SIVA).
Our contribution to the development of telemedicine in Poland has also been acknowledged by the Ministry of Health, which included Medfile and HaloDoctor in the "Healthcare Innovation Map."
Biostat's R&D center status was made possible thanks to the work of high-level specialists, including programmers, statisticians, mathematicians, data analysts, and managers. Year over year, the Biostat team grows by about 20%.
The dedication, responsibility, and desire for continuous development among our team members form the foundation of Biostat’s success. All those who contributed deserve recognition!"
says Ewa Tkocz-Piszczek PhD, Vice President of the Biostat Management Board.
Setting development perspectives is crucial in innovation and R&D activities. Speaking about Biostat's strategic goals and challenges for 2025-2030, the president says:
Our goal is to continue our mission of transferring knowledge from academia to business. This is why our R&D center works closely with universities and companies. Our long-term goal is to expand our infrastructure (staff, technology, and know-how) to comprehensively conduct international clinical trials. We also aim to introduce AI solutions into everyday medical practice and expand the functionality of medical and telemedicine software with additional AI elements. Beyond human medicine, we have been focusing on veterinary medicine, where we want to develop solutions dedicated to pets, their owners, and veterinarians
- concludes Rafał Piszczek.
